D.E. Shaw & Co
RVMD icon

D.E. Shaw & Co’s Revolution Medicines RVMD Stock Holding History

D.E. Shaw & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.4M Sell
1,022,298
-591,432
-37% -$59.7M 0.06% 380
2025
Q4 		$129M Buy
1,613,730
+801,451
+99% +$52.6M 0.07% 327
2025
Q3 		$37.9M Buy
812,279
+152,147
+23% +$5.96M 0.02% 798
2025
Q2 		$24.3M Buy
+660,132
New +$25.4M 0.02% 918
2025
Q1 		– Sell
-14,831
Closed -$649K – 4680
2024
Q4 		$649K Sell
14,831
-25,178
-63% -$1.27M ﹤0.01% 3459
2024
Q3 		$1.81M Buy
40,009
+10,715
+37% +$467K ﹤0.01% 2774
2024
Q2 		$1.14M Sell
29,294
-44,363
-60% -$1.66M ﹤0.01% 3100
2024
Q1 		$2.37M Buy
73,657
+22,584
+44% +$669K ﹤0.01% 2492
2023
Q4 		$1.46M Sell
51,073
-694,198
-93% -$16.7M ﹤0.01% 2889
2023
Q3 		$20.6M Buy
745,271
+301,697
+68% +$8.95M 0.02% 836
2023
Q2 		$11.9M Buy
443,574
+246,741
+125% +$6.05M 0.01% 1208
2023
Q1 		$4.26M Buy
196,833
+134,759
+217% +$3.32M ﹤0.01% 2069
2022
Q4 		$1.48M Sell
62,074
-126,182
-67% -$2.68M ﹤0.01% 3170
2022
Q3 		$3.71M Buy
+188,256
New +$4.14M ﹤0.01% 2405
2022
Q1 		– Sell
-19,541
Closed -$492K – 5882
2021
Q4 		$492K Buy
+19,541
New +$551K ﹤0.01% 4411
2021
Q3 		– Sell
-17,492
Closed -$555K – 5194
2021
Q2 		$555K Sell
17,492
-3,317
-16% -$116K ﹤0.01% 3984
2021
Q1 		$955K Buy
+20,809
New +$933K ﹤0.01% 3150

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co's RVMD Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Revolution Medicines (RVMD) stake by 37% in Q1 2026, selling an estimated $59.7M and leaving 1,022,298 shares worth $99.4M. The position accounts for 0.06% of the portfolio, ranked #380.

D.E. Shaw & Co first reported a position in RVMD in Q1 2021 and has held it in 17 quarters since. The position peaked at $129M in Q4 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • D.E. Shaw & Co held 1,022,298 shares of Revolution Medicines worth $99.4M as of Q1 2026.
  • D.E. Shaw & Co sold 591,432 Revolution Medicines shares in Q1 2026, an estimated $59.7M.
  • Revolution Medicines made up 0.06% of D.E. Shaw & Co's portfolio in Q1 2026, its #380 holding.
  • D.E. Shaw & Co first reported a position in Revolution Medicines in Q1 2021 and has held it in 17 quarters since.
  • D.E. Shaw & Co's Revolution Medicines position peaked at $129M in Q4 2025.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.